Novo Nordisk A/S (NYSE:NVO) Stock Acquired Rep. Marjorie Taylor Greene

Key Points

• Rep. Marjorie Taylor Greene bought shares in Novo Nordisk A/S, investing between $1,001 and $15,000 on August 28th, as disclosed in a filing on August 29th.
• Novo Nordisk A/S stock is currently valued at $56.51, with a market capitalization of $252.29 billion, and has seen its shares fluctuate between a 52-week low of $45.05 and a high of $139.74.
• Recent analyst ratings have downgraded Novo Nordisk A/S from "buy" to "hold," reflecting a more cautious outlook among Wall Street analysts.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 29th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 28th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Southern NYSE: SO on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Morgan Stanley NYSE: MS on 8/28/2025.
• Purchased $15,001 - $50,000 in shares of Exelon NASDAQ: EXC on 8/28/2025.
• Purchased $15,001 - $50,000 in shares of Ryman Hospitality Properties NYSE: RHP on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 8/28/2025.

Novo Nordisk A/S Stock Down 1.8%

Shares of Novo Nordisk A/S stock traded down $0.99 on Friday, hitting $55.15. 15,486,058 shares of the company traded hands, compared to its average volume of 14,631,845. The company has a 50-day moving average price of $59.46 and a 200 day moving average price of $67.62. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $138.22. The company has a market cap of $246.23 billion, a PE ratio of 15.15, a PEG ratio of 1.95 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's payout ratio is currently 22.53%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of NVO. Kingstone Capital Partners Texas LLC boosted its holdings in Novo Nordisk A/S by 301,443.6% during the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock valued at $690,560,000 after acquiring an additional 10,001,898 shares during the period. Nuveen LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at about $370,272,000. Nuveen Asset Management LLC boosted its holdings in Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after acquiring an additional 2,639,693 shares during the period. Two Sigma Investments LP bought a new stake in Novo Nordisk A/S during the fourth quarter valued at about $158,657,000. Finally, Amundi boosted its holdings in Novo Nordisk A/S by 49.1% during the first quarter. Amundi now owns 4,938,507 shares of the company's stock valued at $331,576,000 after acquiring an additional 1,627,051 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NVO shares. Hsbc Global Res cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 31st. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective for the company in a report on Wednesday, August 13th. Finally, Dbs Bank upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $81.00.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.